However, it is also relevant in osteoblastic or mixed lesions (e.g., prostate cancer), as increased bone resorption is often a prerequisite for the subsequent unregulated bone formation, making RANKL a universal therapeutic target across metastatic phenotypes (42). The gene discussed is TNFSF11; the disease is prostate cancer.